Search results for "Prescription"

showing 10 items of 289 documents

Potentially inappropriate use of furosemide in a very elderly population: An observational study

2017

International audience; ObjectiveLittle is known about furosemide prescription modalities in elderly people. We describe furosemide prescription in ambulatory elderly patients.MethodsAll patients aged over 80 years, affiliated to Mutualité Sociale Agricole de Bourgogne, a French regional health insurance plan, with a medical prescription delivered in March 2015, were retrospectively included.ResultsAmong 15 141 patients with a median age of 86 years, comprising 61.3% of women, 3937 patients (26%) had a prescription for furosemide. Severe heart failure was the most common chronic comorbidity (27.7%). Furosemide was considered a long-term therapy for almost all patients (98.7% with prescripti…

Liver CirrhosisMalePediatricsmedicine.medical_specialtyAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsInappropriate Prescribing[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology030204 cardiovascular system & hematologyDrug PrescriptionsNephropathy03 medical and health sciences0302 clinical medicineFurosemidemedicineHumans030212 general & internal medicineMedical prescriptionRenal Insufficiency ChronicDiureticsRetrospective StudiesAged 80 and overHeart Failurebusiness.industryAge FactorsFurosemideRetrospective cohort studyGeneral Medicinemedicine.diseaseComorbidityHeart failureAmbulatoryObservational studyFemalebusinessmedicine.drug
researchProduct

Prescription rates of common medications in patients with decompensated cirrhosis in Germany

2021

Adequate pharmacological treatment is of pivotal importance to improve prognosis in patients with decompensated liver cirrhosis. We studied the adherence to recommended pharmacological treatments as secondary prevention in cirrhotic patients following a first decompensation in German primary care.Using the Disease Analyzer Database, the current study sample included patients with liver cirrhosis who had an initial diagnosis of a first decompensation event between 2015 and 2018 (index date) and a follow-up time of at least 6 months after the index date. Pharmacological treatments following the 6 months after the index date were studied.The study included 1538 patients with a first decompensa…

Liver Cirrhosismedicine.medical_specialtyCirrhosisEsophageal and Gastric Variceschemistry.chemical_compoundSpontaneous bacterial peritonitisInternal medicineAscitesmedicineHumansDecompensationMedical prescriptionHepatic encephalopathybusiness.industryGastroenterologyAscitesHepatologymedicine.diseaseRifaximinPrescriptionsPharmaceutical PreparationschemistryHepatic Encephalopathymedicine.symptomGastrointestinal HemorrhagebusinessZeitschrift für Gastroenterologie
researchProduct

Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19?

2021

Highlights • Antibiotics were a main part of COVID-19 treatments during the first epidemic peak. • Bacterial coinfections seem to be rare, especially if no ICU transfer needed. • We studied the place of antibiotics and the impact on prognosis of patients. • Antibiotics were prescribed if more severe infection and has no impact on prognosis. • We think that antibiotic therapy must be not widely prescribed.

Male0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.drug_class030106 microbiologyAntibioticsInfectious and parasitic diseasesRC109-216Articlelaw.inventionHospitals University03 medical and health sciences0302 clinical medicinelawInternal medicinemedicineHumans030212 general & internal medicineMedical prescriptionPropensity ScoreAgedAged 80 and overUnivariate analysisbusiness.industrySARS-CoV-2Hazard ratioCOVID-19General MedicineMiddle AgedAntibiotic therapyPrognosisIntensive care unitConfidence intervalAnti-Bacterial AgentsCOVID-19 Drug TreatmentHospitalizationInfectious DiseasesRadiological weaponSARS-CoV2Propensity score matchingFemaleFrancebusinessInternational Journal of Infectious Diseases
researchProduct

Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards

2018

no abstract available

MaleAdministration Oral030204 cardiovascular system & hematologyBody Mass IndexOral anticoagulant drug0302 clinical medicineElderlyDrug PrescriptionOlder patientsRetrospective Studie80 and overMedicine030212 general & internal medicineStrokeRandomized Controlled Trials as TopicAged 80 and overAtrial fibrillation; Elderly; Oral anticoagulant drugs; Prescription rate; Internal MedicineAtrial fibrillationStrokeObservational Studies as TopicAtrial fibrillation Elderly Oral anticoagulant drugs Prescription rate Internal MedicineAdministrationOral anticoagulantFemaleHumanOralmedicine.medical_specialtyOral anticoagulant drugsSocio-culturaleDrug Prescriptions03 medical and health sciencesInternal medicineInternal MedicineHumansPrescription rateAgedRetrospective Studiesbusiness.industrySettore MED/09 - MEDICINA INTERNAAnticoagulantAnticoagulantsRetrospective cohort studymedicine.diseaseAtrial fibrillationAtrial fibrillation; Elderly; Oral anticoagulant drugs; Prescription rate; Administration Oral; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Body Mass Index; Drug Prescriptions; Female; Humans; Internal Medicine; Male; Observational Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Stroke; Internal MedicineObservational Studies as TopicbusinessBody mass indexAtrial fibrillation Elderly Oral anticoagulant drugs Prescription rate
researchProduct

The prescription of direct oral anticoagulants in the elderly: An observational study of 19 798 Ambulatory subjects.

2020

International audience; Objective Direct oral anticoagulants (DOACs) are increasingly prescribed to elderly people, but the epidemiologic data for this population remains scarce. We compared the elderly population taking DOACs and those not taking DOACs (noDOAC). Method We included individuals over 75 years old, affiliated to Mutualite Sociale Agricole of Burgundy (a French regional health insurance agency), who had been refunded for a prescribed DOAC between 1st and 30th September 2017. The DAOC group (DAOCG) and noDOAC group (noDOACG) were compared in terms of demographic conditions, registered chronic diseases (RCD), and number and types of prescribed drugs. In the DOACG, we compared the…

MaleAdministration Oral030204 cardiovascular system & hematologyKidney Function Tests0302 clinical medicineRivaroxabanMedicineDisease030212 general & internal medicineProspective StudiesPractice Patterns Physicians'Aged 80 and overeducation.field_of_studyFrailtyVenous ThromboembolismGeneral MedicineMetaanalysisManagement3. Good healthDabigatranHealthCreatinineAmbulatoryPlatelet aggregation inhibitorApixabanFemaleBlood Coagulation TestsFranceSafetymedicine.drugmedicine.medical_specialtyPyridonesPopulationDrug PrescriptionsDabigatran03 medical and health sciencesInternal medicineHumansMedical prescriptioneducationAntihypertensive AgentsAgedRivaroxabanbusiness.industryWarfarinAnticoagulantsBlood Cell CountAtrial-FibrillationChronic DiseasePyrazolesWarfarinbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyPlatelet Aggregation InhibitorsInternational journal of clinical practiceREFERENCES
researchProduct

''Assessment of the use of hypolipidemic agents (HAs), mainly statins, in elderly subjects aged 80 years and more in Burgundy: Analysis of 13,211 pat…

2012

Manckoundia, Patrick | Lorenzini, Mathieu | Disson-Dautriche, Anne | Petit, Jean-Michel | Lorcerie, Bernard | Debost, Emmanuel | Menu, Didier | Pfitzenmeyer, Pierre; International audience; ''Only few studies have investigated the use of HA in elderly subjects and there are no data in very elderly subjects. We assessed the prescription of HA and analyzed the relationship between such prescriptions and frailty markers among persons aged 80 and more in an observational study. We recorded the prescriptions for 13,211 patients aged 80-109 years and affiliated to the "Mutualite-Sociale-Agricole (MSA)'' of Burgundy over a 1-month period. The prescription of a HA among all included patients, and t…

MaleAgingHealth (social science)DiseaseCoronary Artery Disease030204 cardiovascular system & hematologylaw.invention0302 clinical medicineRandomized controlled triallawAVERAGE CHOLESTEROL LEVELS030212 general & internal medicineStrokeHypolipidemic AgentsAged 80 and overFibric AcidsOPEN-LABEL3. Good healthCONTROLLED TRIALHypertensionFemaleFranceSTROKEmedicine.drugmedicine.medical_specialtyAdrenergic beta-AntagonistsDrug Prescriptions03 medical and health sciencesPeripheral Arterial DiseaseDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansCORONARY-HEART-DISEASEMedical prescriptionCARDIOVASCULAR EVENTSMORTALITY''Polypharmacybusiness.industryMORTALITY[SCCO.NEUR]Cognitive science/NeuroscienceCardiovascular Agentsmedicine.disease''CORONARY-HEART-DISEASEPRAVASTATINPhysical therapyPolypharmacyRISK-FACTORSObservational studyGeriatrics and GerontologyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPRIMARY PREVENTIONGerontologyPravastatinPlatelet Aggregation Inhibitors
researchProduct

Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study

2019

The patients’ persistence with osteoporosis treatments is low. This retrospective, multicenter survey showed that almost 30% of osteoporotic patients discontinued the treatment within the first 6 months and that those taking drinkable bisphosphonates were less likely to interrupt the therapy; instead, the use of generic bisphosphonates was associated to a more precocious interruption. Purpose: Low persistence with osteoporosis medications is associated with higher fracture risk. This study aimed to assess the persistence to treatment with oral bisphosphonates among Italian osteoporotic patients under treatment for at least 6 months and to evaluate whether the different oral formulations of …

MaleAgingmedicine.medical_specialtyGeneric drugmedicine.medical_treatmentOsteoporosisDrinkable bisphosphonates; Generic drug; Oral bisphosphonates; Osteoporosis; PersistenceAdministration OralPersistence (computer science)Medication AdherencePersistence03 medical and health sciencesFractures Bone0302 clinical medicineInternal medicineGeneric drugmedicineHumansDrinkable bisphosphonatesGeneric drugOral bisphosphonatesOsteoporosisPersistence030212 general & internal medicineMedical prescriptionAdverse effectAgedRetrospective StudiesOral bisphosphonatesBone Density Conservation AgentsDiphosphonatesbusiness.industryOral bisphosphonatesSettore MED/34 - Medicina Fisica E RiabilitativaBisphosphonateMiddle Agedmedicine.diseaseDiscontinuationLogistic ModelsItalyCase-Control StudiesOsteoporosisFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryOsteoporotic FracturesDrinkable bisphosphonates
researchProduct

Prescription of Antithrombotic Therapy in Older Patients Hospitalized for Transient Ischemic Attack and Ischemic Stroke: The GIFA Study

2004

Background and Purpose— Antithrombotic therapy has been demonstrated as an effective tool for secondary ischemic stroke prevention. Nevertheless, scant data are available on actual prescription of this therapy in clinical practice. Methods— A total of 17 337 patients admitted to geriatric and internal medicine wards participating in the study in the 1993 to 1998 survey period were analyzed. Patients with coded diagnoses of ischemic stroke and transient ischemic attack (TIA) were selected. Data recorded included demographic and clinical characteristics and medication prescription during hospital stay and at discharge. Logistic regression analyses were used to identify conditions associated …

MaleAgingmedicine.medical_specialtypharmacoepidemiologyEpidemiologymedicine.drug_classIschemiaMedication prescriptionNOBrain Ischemiastroke; prevention; aging; antithrombotic therapy; pharmacoepidemiologypreventionFibrinolytic AgentsEpidemiologyAntithromboticmedicineHumansMedical prescriptionStrokeAgedDemographyAntithrombotic therapyAdvanced and Specialized Nursingbusiness.industryAnticoagulantAnticoagulantsOdds ratiomedicine.diseaseHospitalizationStrokeIschemic Attack TransientAcute DiseaseEmergency medicinePhysical therapyFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsStroke
researchProduct

Use of prescription benzodiazepines and related drugs in family caregivers: a nation-wide register-based study

2022

Abstract Background objective indicators of sleep and mental health problems in family caregivers have rarely been reported. Objective to study the use of prescription benzodiazepines and related drugs (BZDRD) in Finnish family caregivers and matched controls. Design prospective follow-up in 2012–17. Setting nationwide register-linkage study. Subjects all individuals who received family caregiver’s allowance in Finland in 2012 (N = 42,256; mean age 67 years; 71% women) and controls matched for age, sex and municipality of residence (N = 83,618). Methods information on purchases of prescription BZDRD, including the number of defined daily doses (DDDs), between 2012 and 2017 was obtained from…

MaleAgingunilääkkeetInsomniainsomniapsychoactive drugsMental disordersunettomuusmielenterveysongelmatolder peoplepsyykenlääkkeetBenzodiazepineshenkinen hyvinvointimielenterveysomaishoitajatPsychoactive drugsHumansHypnotics and SedativesProspective StudiesAgedinformal caregivinghenkinen pahoinvointiGeneral Medicinemental disordersAgeingPrescriptionsCaregiversageingInformal caregiving3121 General medicine internal medicine and other clinical medicineFemaleGeriatrics and GerontologyOlder peopleikääntyneetbentsodiatsepiinit
researchProduct

Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.

2014

BACKGROUND This large prospective multicentre cohort study aimed to improve knowledge of therapy for chronic hepatitis C (CHC) in real clinical practice. METHODS A diverse population of adults with CHC including patients with comorbid conditions, laboratory abnormalities and demographic features [comorbidities or special populations (CSP)] who were under-represented or excluded from peginterferon registration studies was treated with peginterferon α-2a (40 kDa) or α-2b (12 kDa) plus ribavirin at the investigator's discretion. RESULTS During the study, 5399 treatment-naive patients [2527 (46.8%) with CSP] received peginterferon α-2a (n=3513, 65.1%) or peginterferon α-2b (n=1886, 34.9%). The …

MaleCirrhosisTime FactorsComorbidityHepacivirusmedicine.disease_causePolyethylene Glycolschemistry.chemical_compoundRecurrencepeginterferonProspective Studiesspecial populationAged 80 and overbiologyRemission InductionGastroenterologyvirus diseasesMiddle AgedViral LoadRecombinant ProteinsTreatment OutcomeItalyHCVRNA ViralDrug Therapy CombinationFemalesustained virological responseCohort studyAdultcomorbiditiemedicine.medical_specialtyAdolescentGenotypeHepatitis C virusInterferon alpha-2Antiviral AgentsYoung AdultChronic hepatitisInternal medicineRibavirinmedicineHumansIn patientMedical prescriptionAgedHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseasechemistryAlanine transaminaseImmunologybiology.proteinbusinessEuropean journal of gastroenterologyhepatology
researchProduct